Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Nektar again looks to bempeg to sweeten its valuation
The depressed company’s bempegaldesleukin, which underwhelmed in melanoma, now faces two key near-term clinical data readouts.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Asco 2021 – Alkermes’s disappointment hones melanoma niche focus
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
